company background image
BIT

BiotronASX:BIT Stock Report

Market Cap

AU$37.2m

7D

0%

1Y

-42.4%

Updated

18 Oct, 2021

Data

Company Financials
BIT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BIT Overview

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Biotron
Historical stock prices
Current Share PriceAU$0.053
52 Week HighAU$0.046
52 Week LowAU$0.094
Beta-1.92
1 Month Change0%
3 Month Change-8.62%
1 Year Change-42.39%
3 Year Change-75.91%
5 Year Change10.42%
Change since IPO-88.09%

Recent News & Updates

May 26
Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans

Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Feb 10
We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate

We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Dec 19
What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?

What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?

The CEO of Biotron Limited ( ASX:BIT ) is Michelle Miller, and this article examines the executive's compensation...

Shareholder Returns

BITAU BiotechsAU Market
7D0%0.8%1.7%
1Y-42.4%-0.3%20.3%

Return vs Industry: BIT underperformed the Australian Biotechs industry which returned 1.5% over the past year.

Return vs Market: BIT underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is BIT's price volatile compared to industry and market?
BIT volatility
BIT Beta-1.92
Industry Beta1.61
Market Beta1

Stable Share Price: BIT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: BIT's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999n/aMichelle Millerhttps://www.biotron.com.au

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs.

Biotron Fundamentals Summary

How do Biotron's earnings and revenue compare to its market cap?
BIT fundamental statistics
Market CapAU$37.20m
Earnings (TTM)-AU$3.19m
Revenue (TTM)AU$1.46m

25.5x

P/S Ratio

-11.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIT income statement (TTM)
RevenueAU$1.46m
Cost of RevenueAU$0
Gross ProfitAU$1.46m
ExpensesAU$4.66m
Earnings-AU$3.19m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0046
Gross Margin100.00%
Net Profit Margin-218.50%
Debt/Equity Ratio0%

How did BIT perform over the long term?

See historical performance and comparison

Valuation

Is Biotron undervalued compared to its fair value and its price relative to the market?

9.64x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BIT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BIT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BIT is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: BIT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIT is overvalued based on its PB Ratio (9.6x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Biotron forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Biotron performed over the past 5 years?

-10.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIT is currently unprofitable.

Growing Profit Margin: BIT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIT is unprofitable, and losses have increased over the past 5 years at a rate of 10.6% per year.

Accelerating Growth: Unable to compare BIT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: BIT has a negative Return on Equity (-82.69%), as it is currently unprofitable.


Financial Health

How is Biotron's financial position?


Financial Position Analysis

Short Term Liabilities: BIT's short term assets (A$4.3M) exceed its short term liabilities (A$451.2K).

Long Term Liabilities: BIT's short term assets (A$4.3M) exceed its long term liabilities (A$12.3K).


Debt to Equity History and Analysis

Debt Level: BIT is debt free.

Reducing Debt: BIT has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BIT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BIT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 2.7% each year.


Dividend

What is Biotron current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

19.3yrs

Average management tenure


CEO

Michelle Miller

19.33yrs

Tenure

AU$405,073

Compensation

Dr. Michelle Miller, B.Sc., M.Sc., PhD, GCertAppFin (Finsia), serves as Chief Executive Officer of Biotron Ltd. and serves as its Managing Director since June 21, 2002. Dr. Miller served as Investment Mana...


CEO Compensation Analysis

Compensation vs Market: Michelle's total compensation ($USD300.66K) is about average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Michelle's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BIT's management team is seasoned and experienced (19.3 years average tenure).


Board Members

Experienced Board: BIT's board of directors are considered experienced (9.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biotron Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Biotron Limited
  • Ticker: BIT
  • Exchange: ASX
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$37.202m
  • Shares outstanding: 701.93m
  • Website: https://www.biotron.com.au

Number of Employees


Location

  • Biotron Limited
  • 66 Hunter Street
  • Level 2
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 15:17
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.